Eli Lilly and Co. (NYSE:LLY) unveiled new data on Tuesday from LUCENT-3, the single-arm long-term Phase 3 open-label extension of LUCENT-1 and LUCENT-2, which evaluated the efficacy and safety of mirikizumab in patients with ulcerative colitis for an additional three years of treatment (up to four years total).
The data showed that Omvoh (mirikizumab-mrkz) is the first and only interleukin-23p19 (IL-23p19) inhibitor to help patients with moderately to severely active ulcerative colitis achieve sustained, long-term outcomes for up to four years.
